Is AGIO a Buy? What to Consider in 2026
Short answer
The bull case for Agios Pharmaceuticals develops medicines for rare hematologic (AGIO) rests on Mitapivat franchise expansion: Agios is trying to grow mitapivat from a small PK-deficiency drug into a multi-disease franchise. Revenue (TTM) is ~$66M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest. Whether AGIO is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia. The company is pursuing accelerated approval of mitapivat in sickle cell disease and, as of July 2026, the FDA granted Priority Review to that application. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib). The investment picture is a classic emerging-biotech profile. Product revenue is real but small (roughly $54 million in full-year 2025 and about $21 million in Q1 2026, more than doubling year over year), while research and commercial spending keep the company deeply unprofitable, with net losses of over a dollar-and-a-half per share per quarter. A cash and investments balance of around $1 billion as of March 2026 funds the pipeline through several near-term catalysts. The upside case rests on mitapivat expanding into far larger indications like sickle cell and thalassemia; the downside case is that trials disappoint (as the tebapivat lower-risk MDS program did in 2026) and the franchise stays niche while cash burns.
What's the case for buying AGIO?
1. Mitapivat franchise expansion
Agios is trying to grow mitapivat from a small PK-deficiency drug into a multi-disease franchise. AQVESME launched in US thalassemia in 2026, and the company is pursuing accelerated FDA approval in sickle cell disease, a much larger market. Each new indication meaningfully widens the potential patient base for a single molecule.
2. Sickle cell Priority Review
The FDA granted Priority Review to Agios' supplemental application for mitapivat in sickle cell disease (announced July 2026), which shortens the review timeline. A sickle cell approval would be the single largest addressable-market event for the company, and the stock reacted sharply to the news.
3. Strong balance sheet plus Servier royalty
Roughly $1 billion in cash and investments as of March 2026 funds operations through multiple pipeline readouts without immediate financing pressure. Agios also collects a royalty on US sales of Servier's Voranigo, a non-dilutive stream tied to a growing brain-cancer drug.
4. Next-generation PK activator pipeline
Beyond mitapivat, Agios is developing tebapivat, a next-generation PK activator, with a Phase 2 sickle cell readout expected in the second half of 2026. The company frames 2026 as a year of multiple value-driving inflection points across its hematology pipeline.
What are the risks to AGIO?
Agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest. The business is heavily dependent on a single molecule, so a negative trial or regulatory setback is materially damaging, as shown when Agios halted tebapivat development in lower-risk myelodysplastic syndromes in 2026 after the trial missed its efficacy threshold. Sickle cell and thalassemia are competitive markets with gene therapies and other novel agents, and accelerated approval requires a confirmatory trial that could still fail. Ongoing R&D and commercial spending will continue to burn cash, and while the balance sheet is strong today, sustained losses without pipeline success would eventually pressure it.
How is AGIO valued? (as of JUNE 2026)
Snapshot for AGIO as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$66M
- FY2025 revenue: ~$54M
- Q1 2026 revenue: ~$20.7M (up ~138% YoY)
- Q1 2026 GAAP EPS: ~-$1.69
- Cash & investments: ~$1.0B (Mar 2026)
- Market cap: ~$2.1B
Agios trades at a large multiple of its small product revenue, reflecting a valuation driven by pipeline potential rather than current earnings. The company is unprofitable, with R&D (~$81M) and SG&A (~$48M) in Q1 2026 far exceeding revenue. The roughly $1 billion cash balance represents a large share of the market capitalization, which cushions financing risk but also signals that the market is paying primarily for future indications like sickle cell disease.
How do you decide if AGIO is a buy?
Rather than asking whether AGIO is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold AGIO indirectly through an index or sector ETF before adding more.
For the full picture, see the AGIO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AGIO against your real portfolio and see your actual exposure before deciding.
The bottom line on AGIO
The bottom line: Agios Pharmaceuticals develops medicines for rare hematologic's story right now is Mitapivat franchise expansion, with revenue (ttm) at ~$66M. If you believe that narrative continues, the call is about sizing AGIO sensibly and checking overlap with what you own; if you doubt it (the risk: agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around AGIO with Walnut
Use Agios Pharmaceuticals develops medicines for rare hematologic as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is AGIO a good stock to buy right now?
+
The case for Agios Pharmaceuticals develops medicines for rare hematologic right now is Mitapivat franchise expansion, with revenue (ttm) at ~$66M. If you believe that thesis holds, AGIO is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Agios Pharmaceuticals develops medicines for rare hematologic do?
+
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases.
What are the main risks of AGIO?
+
Agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest. The business is heavily dependent on a single molecule, so a negative trial or regulatory setback is materially damaging, as shown when Agios halted tebapivat development in lower-risk myelodysplastic syndromes in 2026 after the trial missed its efficacy threshold. Sickle cell and thalassemia are competitive markets with gene therapies and other novel agents, and accelerated approval requires a confirmatory trial that could still fail. Ongoing R&D and commercial spending will continue to burn cash, and while the balance sheet is strong today, sustained losses without pipeline success would eventually pressure it.
What does Agios Pharmaceuticals do?
+
Agios develops medicines for rare hematologic (blood) diseases. Its main product is mitapivat, a pyruvate kinase activator sold as PYRUKYND for PK deficiency and AQVESME for thalassemia, and it is pursuing approval in sickle cell disease.
Is AGIO profitable?
+
No. As of Q1 2026 Agios reported a GAAP loss of about $1.69 per share. Research and commercial spending far exceed its roughly $21 million of quarterly product revenue, so the company remains deeply unprofitable.
How much revenue does Agios generate?
+
Agios reported about $54 million in full-year 2025 product revenue and roughly $20.7 million in Q1 2026, up about 138% year over year. Trailing-twelve-month revenue is in the neighborhood of $66 million as of mid-2026.
What is mitapivat (PYRUKYND and AQVESME)?
+
Mitapivat is an oral pyruvate kinase activator. It is approved as PYRUKYND for pyruvate kinase deficiency and as AQVESME for thalassemia, and Agios is seeking accelerated approval for its use in sickle cell disease.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell AGIO; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.